Medication info
Rozal Plus Tablet

Rozal Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Korea United Pharm, Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 200607930 · Notified 2006.09.18 · Insurance code 644300950

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or more. Administration to these patients is not recommended, as loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment.
Child dose
○ Children (under 18 years) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Korea United Pharm, Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication helps effectively control blood pressure for patients with hypertension who have difficulty achieving control with monotherapy. It is used as an additional treatment when blood pressure does not sufficiently lower with a single therapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine when the desired effect is not achieved with monotherapy. 1. Replacement therapy: A combination regimen of individually dose-adjusted losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even when their blood pressure is controlled at this dose: Treatment may be started with one tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Thereafter, monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of one tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose in patients with a creatinine clearance of 30 mL/min or more. Administration to these patients is not recommended, as loop diuretics are preferable to thiazide drugs in patients with more severe renal impairment. ○ Patients with hepatic impairment Administration to these patients is not recommended because this medicine cannot provide the initial dose of losartan potassium, 25 mg, required for patients with hepatic impairment who need dose adjustment.

Child dose

○ Children (under 18 years) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm or death to the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be given to certain patients. For example, patients who are allergic to this medication or its components, have severely impaired kidney function, have severe liver dysfunction, or are pregnant should not take it. Additionally, patients with very low blood pressure, kidney problems, hypercalcemia, or gout should use this medication cautiously and consult their doctor before taking it. Regular checks of blood pressure, kidney function, and electrolyte levels should be performed during the use of this medication to monitor for abnormalities. This medication may increase potassium levels in the blood, so it can be dangerous to take it with potassium supplements or other medications that contain potassium without consulting a doctor. The hydrochlorothiazide component may cause electrolyte imbalances, so caution is advised especially if symptoms like vomiting or diarrhea occur; severe symptoms should be reported to medical personnel immediately. Some patients may experience side effects such as skin rash, headache, dizziness, or cough, and if a severe allergic reaction occurs, the medication should be stopped immediately and a healthcare professional consulted. During treatment, avoid excessive sun exposure, and report any unusual skin changes to a doctor immediately. This medication has insufficient experience for use in children and adolescents, so it should not be administered to them. In elderly patients, adverse reactions may occur more frequently, so they should take it with caution. Caution should be taken in case of dizziness or drowsiness while driving or operating machinery. It is advisable to avoid grapefruit juice during treatment, and if other medications are being taken, inform the doctor or pharmacist as there may be interactions with other drugs. This medication should be stored out of reach of children and kept in its original container with the lid tightly closed.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin desquamation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory deprivation
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuralgia
  • panic disorder
  • sensory disturbances
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus obstruction
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitive reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasm
  • agitation
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • mucocutaneous syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • temporary blurred vision
  • yellow vision
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly sealed container that blocks light. The appropriate storage temperature is between 1°C and 30°C at room temperature.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.